CARMEL, Ind., Nov. 04, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...
Read Neuraxis, Inc. (NRXS) Q2 FY2025 earnings call transcript on Yahoo Finance to keep your investing strategy up to date with all of the latest information ...
NeurAxis announced strong Q1 2025 results, with a 39% revenue increase and expanded payer coverage, while operating loss improved. NeurAxis, Inc. reported a strong first quarter for 2025, with ...
CARMEL, Ind., May 15, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children ...
NeurAxis reports 43% revenue growth in Q4 2024, significant advancements in insurance coverage, and FDA approvals for its technologies. NeurAxis, Inc. reported its fourth quarter and fiscal year 2024 ...
CARMEL, Ind., Nov. 05, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children ...
Read Neuraxis, Inc. (NRXS) Q3 FY2025 earnings call transcript on Yahoo Finance to keep your investing strategy up to date with all of the latest information ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results